Devoted Health has just authorized a new Series D preferred stock which could increase the valuation to $13 billion if all Series D shares are issued. The healthcare insurance company is previously backed by Andreessen Horowitz, Premji Invest, Uprising Capital, Obvious Ventures, Venrock, F-Prime Capital, and Maverick Capital to name a few. The most recent Series D round follows $217 million raised for Series C. The terms surrounding the Series D include Senior liquidation preference to all other preferred, and conventional convertible meaning they will not participate with common stock if there are remaining proceeds. The most recent price per share is $56.2503, an up round from Series C at $17.7104.